Movers and Shakers within Pharma

Miss Chanice Henry
Posted: 05/03/2016

Pharma IQ takes a look at some of the industry’s most prestigious movers and shakers causing ripples in the market over the last few months.

CEO Sir Andrew Witty to retire after 32 years at GSK

Last month, GSK plc revealed to shareholders that it’s CEO of 10 years Sir Andrew Witty has indicated his intention to retire from the company. The move is scheduled to occur at the end of Q1 next year and until then the firm is searching for his successor.  Sir Witty spent a total of 32 years at the pharmaceutical firm.

Martin Shkreli steps down

Last month it was announced that Martin Shkreli, who faced fierce media criticism over the pricing of HIV drug Daraprim, stepped down from his position as CEO at Turing Pharmaceuticals, with Ron Tilles stepping in as interim CEO. 

Download FREE Brochure
Interested in learning more about this topic?
Download the Agenda for Packaging and Labeling 2016 Summit

In June this year, join 100+ pharma industry professions for Europe’s most senior-level industry-led packaging event. Since 2011 we have been bringing together pharmaceutical leaders from all functional groups acrosspackaging, serialisation, artwork andlabelling for three influential days of case-study driven discussions. 

Graham Walker heads from AstraZeneca to Idea Pharma

In response to the new recruit, who has over 20 years of industry experience, in an online statement Mike Rea IDEA Pharma’s CEO commented: “We’re constantly on the hunt for the very best intellectual, creative and innovative minds, as we’re recognised leaders now in this industry. Graham’s appointment further strengthens our position.” 

Mike Pearson to step down from CEO position at Valeant

Valeant Pharmaceuticals announced that Michael Pearson’s term as CEO for the company would be coming to an end once his successor is named.

"It's been a privilege to lead Valeant for the past eight years," said J. Michael Pearson, chief executive officer. "While I regret the controversies that have adversely impacted our business over the past several months, I know that Valeant is a strong and resilient company, and I am committed to doing everything I can to ensure a smooth transition to new leadership."

Lumos Pharma welcomes David M Weiner

David Weiner joins the company to fill Lumos Pharma’s Inc Chief Medical Officer position.  He previously performed the same role at Tyr Pharma and Proteostasis Therapeutics.  In reaction to his new role with the biotech firm, Dr Weiner said: "I am excited to be joining Lumos Pharma at this important time in the company's evolution as we prepare for our first formal meeting with the FDA, and continue to advance the development of our pipeline. "

Cancer Genomics firm appoints ex-Archimedes Pharma Ltd CEO

Inviata Limited recently appointed Jeffrey Buchalter as its Non-executive Director and Board Chairman. 

Have Your Say
Rate this feature and give us your feedback in the comments section below
Miss Chanice Henry
Posted: 05/03/2016

Pharma IQ Members

EVENTS OF INTEREST

London, UK
November 27 - 28, 2017
Vienna Marriott Hotel, Vienna, Austria
November 26 - 28, 2017
Hilton Brussels Grand Place, Brussels, Belgium
November 27 - 29, 2017